Next‐generation peptide vaccines for advanced cancer

Many clinical trials of peptide vaccines have been carried out since the first clinical trial of a melanoma antigen gene‐1‐derived peptide‐based vaccine was reported in 1995. The earlier generations of peptide vaccines were composed of one to several human leukocyte antigen class I‐restricted CTL‐epitope peptides of a single human leukocyte antigen type. Currently, various types of next‐generation peptide vaccines are under development. In this review, we focus on the clinical trials of the following categories of peptide vaccines mainly published from 2008 to 2012: (i) multivalent long peptide vaccines; (ii) multi‐peptide vaccines consisting of CTL‐ and helper‐epitopes; (iii) peptide cocktail vaccines; (iv) hybrid peptide vaccines; (v) personalized peptide vaccines; and (vi) peptide‐pulsed dendritic cell vaccines. (Cancer Sci 2013; 104: 15–21)

[1]  Hiroaki Tanaka,et al.  Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival , 2012, Nature Medicine.

[2]  T. Sasada,et al.  Phase II study of personalized peptide vaccination for castration‐resistant prostate cancer patients who failed in docetaxel‐based chemotherapy , 2012, The Prostate.

[3]  K. Shirouzu,et al.  Personalized peptide vaccination in patients with refractory non-small cell lung cancer. , 2012, International journal of oncology.

[4]  T. Sasada,et al.  Immunological evaluation of personalized peptide vaccination in refractory small cell lung cancer , 2012, Cancer science.

[5]  S. Steinberg,et al.  A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients , 2012, Cancer Immunology, Immunotherapy.

[6]  S. Todo,et al.  First clinical trial of cancer vaccine therapy with artificially synthesized helper/ killer‐hybrid epitope long peptide of MAGE‐A4 cancer antigen , 2012, Cancer science.

[7]  Y. Doki,et al.  A phase I study of vaccination with NY‐ESO‐1f peptide mixed with Picibanil OK‐432 and Montanide ISA‐51 in patients with cancers expressing the NY‐ESO‐1 antigen , 2011, International journal of cancer.

[8]  S. Baba,et al.  A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin , 2011, BJU international.

[9]  M. Ross,et al.  Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Wolchok,et al.  CTLA-4 blockade increases antigen-specific CD8+ T cells in prevaccinated patients with melanoma: three cases , 2011, Cancer Immunology, Immunotherapy.

[11]  H. Akaza,et al.  A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low‐dose estramustine in HLA‐A24‐positive patients with castration‐resistant prostate cancer , 2011, The Prostate.

[12]  S. Baba,et al.  601 A PHASE I STUDY OF PERSONALIZED PEPTIDE VACCINATION FOR ADVANCED UROTHELIAL CARCINOMA PATIENTS WHO FAILED TREATMENT WITH METHOTREXATE, VINBLASTINE, ADRIAMYCIN AND CISPLATIN , 2011 .

[13]  K. Blackwell,et al.  MHC Class I–Presented Tumor Antigens Identified in Ovarian Cancer by Immunoproteomic Analysis Are Targets for T-Cell Responses against Breast and Ovarian Cancer , 2011, Clinical Cancer Research.

[14]  K. Kurisu,et al.  Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Engh,et al.  Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Daohai Yu,et al.  Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma , 2010, Clinical Cancer Research.

[17]  P. Greenberg,et al.  Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909 , 2010, Cancer Immunology, Immunotherapy.

[18]  T. Tani,et al.  A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. , 2010, Oncology reports.

[19]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[20]  J. Wolchok,et al.  Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. , 2010, Blood.

[21]  W. Travis,et al.  WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer , 2010, Cancer Immunology, Immunotherapy.

[22]  S. Perez,et al.  Results from a Phase I Clinical Study of the Novel Ii-Key/HER-2/neu(776–790) Hybrid Peptide Vaccine in Patients with Prostate Cancer , 2010, Clinical Cancer Research.

[23]  H. Kumon,et al.  A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer , 2010, Cancer Immunology, Immunotherapy.

[24]  S. H. van der Burg,et al.  Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. , 2009, The New England journal of medicine.

[25]  M. Ross,et al.  Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial , 2009, Clinical Cancer Research.

[26]  Cécile Gouttefangeas,et al.  Novel multi‐peptide vaccination in Hla‐A2+ hormone sensitive patients with biochemical relapse of prostate cancer , 2009, The Prostate.

[27]  S. H. van der Burg,et al.  Induction of p53-Specific Immunity by a p53 Synthetic Long Peptide Vaccine in Patients Treated for Metastatic Colorectal Cancer , 2009, Clinical Cancer Research.

[28]  K. Itoh,et al.  Recent advances in cancer vaccines: an overview. , 2008, Japanese journal of clinical oncology.

[29]  N. Senzer,et al.  Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Murray,et al.  Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  C. Slingluff,et al.  A Multipeptide Vaccine is Safe and Elicits T-cell Responses in Participants With Advanced Stage Ovarian Cancer , 2008, Journal of immunotherapy.

[32]  S. H. van der Burg,et al.  Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity , 2008, Clinical Cancer Research.

[33]  H. Kanayama,et al.  Phase I trial of personalized peptide vaccination for cytokine‐refractory metastatic renal cell carcinoma patients , 2007, Cancer science.

[34]  C. Slingluff,et al.  Immunologic and Clinical Outcomes of a Randomized Phase II Trial of Two Multipeptide Vaccines for Melanoma in the Adjuvant Setting , 2007, Clinical Cancer Research.

[35]  B. Kavanagh,et al.  Vaccination of Metastatic Colorectal Cancer Patients With Matured Dendritic Cells Loaded With Multiple Major Histocompatibility Complex Class I Peptides , 2007, Journal of immunotherapy.

[36]  S. Korn,et al.  An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer. , 2007, Lung cancer.

[37]  Yuji Sato,et al.  Immunological evaluation of personalized peptide vaccination in combination with a 5‐fluorouracil derivative (TS‐1) for advanced gastric or colorectal carcinoma patients , 2007, Cancer science.

[38]  K. Itoh,et al.  Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer , 2007, The Prostate.

[39]  M. Oka,et al.  Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer , 2007, Cancer science.

[40]  H. Johnsen,et al.  Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers , 2007, Cancer Immunology, Immunotherapy.

[41]  C. Blackwell,et al.  Ii-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccines , 2006, Expert opinion on biological therapy.

[42]  Akira Yamada,et al.  Personalized peptide vaccines: A new therapeutic modality for cancer , 2006, Cancer science.

[43]  K. Itoh,et al.  Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: an analysis of prognostic factors in the treatment. , 2006, Oncology research.

[44]  M. Shigemori,et al.  Immunologic Evaluation of Personalized Peptide Vaccination for Patients with Advanced Malignant Glioma , 2005, Clinical Cancer Research.

[45]  K. Itoh,et al.  Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA‐A24+ HRPC patients , 2005, The Prostate.

[46]  K. Itoh,et al.  Immunological monitoring during combination of patient‐oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer , 2004, The Prostate.

[47]  H. Yamana,et al.  A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients , 2004, British Journal of Cancer.

[48]  K. Ushijima,et al.  Vaccination with Predesignated or Evidence-Based Peptides for Patients with Recurrent Gynecologic Cancers , 2004, Journal of immunotherapy.

[49]  H. Yamana,et al.  Phase I trial of patient‐oriented vaccination in HLA‐A2‐positive patients with metastatic hormone‐refractory prostate cancer , 2004, Cancer science.

[50]  K. Itoh,et al.  Induction of cellular and humoral immune responses to tumor cells and peptides in HLA‐A24 positive hormone‐refractory prostate cancer patients by peptide vaccination , 2003, The Prostate.

[51]  H. Yamana,et al.  Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre‐existing cellular response to peptide , 2003, Cancer science.

[52]  H. Yamana,et al.  Peptide Vaccination for Patients With Melanoma and Other Types of Cancer Based on Pre-existing Peptide-Specific Cytotoxic T-Lymphocyte Precursors in the Periphery , 2003, Journal of immunotherapy.

[53]  K. Shirouzu,et al.  Immunological evaluation of CTL precursor‐oriented vaccines for advanced lung cancer patients , 2003, Cancer science.

[54]  Yao-Tseng Chen,et al.  A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[55]  S. Kurtzman,et al.  Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. , 1996, Cancer research.

[56]  C Oseroff,et al.  Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. , 1994, Immunity.

[57]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.

[58]  S. H. van der Burg,et al.  Long‐term clinical and immunological effects of p53‐SLP® vaccine in patients with ovarian cancer , 2012, International journal of cancer.